Last reviewed · How we verify
4 weeks of Nicotine lozenge
4 weeks of Nicotine lozenge is a Small molecule drug developed by University of Virginia. It is currently in Phase 1 development. Also known as: Sunmark Nicotine Polacrilex Lozenge, Habitrol Nicotine Lozenge, Nicotinell Nicotine Lozenge, Nicorette Lozenge.
At a glance
| Generic name | 4 weeks of Nicotine lozenge |
|---|---|
| Also known as | Sunmark Nicotine Polacrilex Lozenge, Habitrol Nicotine Lozenge, Nicotinell Nicotine Lozenge, Nicorette Lozenge |
| Sponsor | University of Virginia |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Any Related Adverse Event
- Any NON-Related and Non-Serious Adverse Events
- Mild side effects of nicotine replacement therapy
- Headache
- Dizziness
- Nausea / upset stomach
- Skin Irritation
- Sore or dry mouth
- Sleeplessness / trouble sleeping
- Bad or vivid dreams / nightmares
Key clinical trials
- Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers (NA)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder (PHASE2)
- Rural Smoking Cessation (NA)
- Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors (NA)
- Mindfulness-based Smoking Cessation Enhanced With Mobile Technology (NA)
- Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings (NA)
- Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 4 weeks of Nicotine lozenge CI brief — competitive landscape report
- 4 weeks of Nicotine lozenge updates RSS · CI watch RSS
- University of Virginia portfolio CI
Frequently asked questions about 4 weeks of Nicotine lozenge
What is 4 weeks of Nicotine lozenge?
4 weeks of Nicotine lozenge is a Small molecule drug developed by University of Virginia.
Who makes 4 weeks of Nicotine lozenge?
4 weeks of Nicotine lozenge is developed by University of Virginia (see full University of Virginia pipeline at /company/university-of-virginia).
Is 4 weeks of Nicotine lozenge also known as anything else?
4 weeks of Nicotine lozenge is also known as Sunmark Nicotine Polacrilex Lozenge, Habitrol Nicotine Lozenge, Nicotinell Nicotine Lozenge, Nicorette Lozenge.
What development phase is 4 weeks of Nicotine lozenge in?
4 weeks of Nicotine lozenge is in Phase 1.
What are the side effects of 4 weeks of Nicotine lozenge?
Common side effects of 4 weeks of Nicotine lozenge include Any Related Adverse Event, Any NON-Related and Non-Serious Adverse Events, Mild side effects of nicotine replacement therapy, Headache, Dizziness, Nausea / upset stomach.
Related
- Manufacturer: University of Virginia — full pipeline
- Also known as: Sunmark Nicotine Polacrilex Lozenge, Habitrol Nicotine Lozenge, Nicotinell Nicotine Lozenge, Nicorette Lozenge
- Compare: 4 weeks of Nicotine lozenge vs similar drugs
- Pricing: 4 weeks of Nicotine lozenge cost, discount & access